Latest News
Vor Biopharma Inc.
- Learn Why The Bull Case For Vor Biopharma Stock Could Change Following Phase 3 Kidney Trial Results
- Vor Bio (VOR) Reports Positive Phase 3 Trial Results for Telitac
- Vor Bio says its experimental drug slowed loss of kidney function in late-stage study
- VOR Initiates Coverage On Vor Biopharma -- Rating "Outperform" b
- William Blair Starts Vor Biopharma, Inc. (VOR) at Outperform
- How Investors May Respond To Vor Biopharma (VOR) Phase 3 gMG Data
- Form 4 Vor Biopharma Inc For: 5 October By Investing.com
- Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Headlines from the last 30 days, linking to the original publishers. See all market news →